BioSpace News Archive

March of Dimes, the nation’s leader in the fight for the health of all moms and babies, is pleased to announce the availability of funds for research grants to address the heath threats facing pregnant women and babies during the COVID

TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today announced tha

Capricor Therapeutics (NASDAQ: CAPR) a clinical-stage biotechnology company focused on the development of first-in-class cell and exosome-based therapeutics for the treatment and prevention of diseases, announced today that it will release its financial results for the second quarter ended June 30, 2020, after the market close on Thursday, August 6, 2020. Company management will host a conference call and webcast to discuss its financial resul

Looking to grow by scaling operations and accelerating R&D efforts, Kebotix, a Cambridge-based technology platform company for new chemicals and materials, is extending its labs operations in the Boston area at C2I, a chemistry-focused accelerator in Woburn.

Masimo (NASDAQ: MASI) today announced that it has entered into a partnership with the National Basketball Association (NBA) to be its official supplier of pulse oximetry. As teams return to play, Masimo is supplying the NBA with MightySat ® fingertip pulse oximeters on its campus in Orlando, Florida. This press release features multi

Medicinal Genomics Corp. (MGC), a pioneer in harnessing cannabis genomics to improve the agricultural productivity, safety and transparency of cannabis, today announced that SD PharmLabs, a multistate testing lab organization, has selected Medicinal Genomics’ PathoSEEK® qPCR platform for microbial testing in its Texas hemp lab, the first in that state.

Two U.S. FDA approvals in second quarter 2020 Second quarter 2020 total revenue of $61.7 million and Crysvita revenue in Ultragenyx territories of $32.4 million Maintains full year 2020 guidance based on global COVID-19 impact to date

Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today provided a business update and announced financial results for the second quarter ended June 30, 2020.

Increased Total Revenue 1% Year-over-Year to $30.7 Million Accelerated the Commercial Integration of Parcus Medical and Arthrosurface Organizations Launching Seven FDA-Cleared Orthopedic and Sports Medicine Products Through Q3 2020

The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the U.S. Food and Drug Administration (FDA) has approved an expanded indication for STELARA® (ustekinumab) as a treatment for pediatric patients (6-11 years of age) who struggle with the skin lesions or plaques associated with moderate to severe plaque psoriasis (PsO)